

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR STUDY.....	1
SCOPE OF STUDY.....	1
METHODOLOGY AND INFORMATION SOURCES.....	2
ANALYST CREDENTIALS.....	2
RELATED BCC REPORTS.....	2
DISCLAIMER.....	3
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 4
EXECUTIVE SUMMARY.....	4
<i>SMMARY TABLE TOTAL MARKET FOR DEPRESSIVE AND ANXIETY</i> <i>DISORDERS, THROUGH 2014 (\$ MILLIONS)</i>	 5
<i>SUMMARY FIGURE TOTAL MARKET FOR DEPRESSIVE AND</i> <i>ANXIETY DISORDERS, 2007-2014 (\$ MILLIONS)</i>	 5
 CHAPTER THREE: INDUSTRY OVERVIEW.....	 6
HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY.....	 6
HISTORICAL PERSPECTIVE OF THE ... (CONTINUED).....	7
HISTORICAL PERSPECTIVE OF THE ... (CONTINUED).....	8
HISTORICAL PERSPECTIVE OF THE ... (CONTINUED).....	9
HISTORICAL PERSPECTIVE OF THE ... (CONTINUED).....	10
HISTORICAL PERSPECTIVE OF THE ... (CONTINUED).....	11
HISTORICAL PERSPECTIVE OF THE ... (CONTINUED).....	12
HISTORICAL PERSPECTIVE OF THE ... (CONTINUED).....	13
INTRODUCTION TO THE NERVOUS SYSTEM AND BRAIN.....	14
INTRODUCTION TO THE ... (CONTINUED).....	15
BLOOD-BRAIN BARRIER.....	16
DEMOGRAPHICS.....	16
<i>TABLE 1 WORLD POPULATION BY SELECTED GEOGRAPHICAL</i> <i>REGION, 2008–2050 (MILLIONS)</i>	 17
<i>FIGURE 1 WORLD POPULATION BY SELECTED GEOGRAPHICAL</i> <i>REGION, 2008–2050 (MILLIONS)</i>	 18
<i>TABLE 2 ESTIMATED WORLD POPULATION BY AGE AND</i> <i>GEOGRAPHICAL REGION, 2008 (MILLIONS)</i>	 18
<i>FIGURE 2 ESTIMATED WORLD POPULATION BY AGE AND</i> <i>GEOGRAPHICAL REGION, 2008 (MILLIONS)</i>	 19
<i>TABLE 3 POPULATION OVER 65 BY YEAR AND REGION, 2008-2050</i> <i>(%)</i>	 20
<i>FIGURE 3 POPULATION OVER 65 BY YEAR AND REGION, 2008-2050</i>	20
PREVALENCE OF MENTAL DISORDERS.....	20
<i>TABLE 4 BEST ESTIMATE 1-YEAR PREVALENCE RATES BASED ON</i> <i>ECA AND NCS, AGES 18-54 (%)</i>	 21
<i>TABLE 4 (CONTINUED)</i>	22

<i>TABLE 5 PERCENTAGE OF INDIVIDUALS 12 YEARS AND OLDER WITH DEPRESSION BY DEMOGRAPHIC CHARACTERISTIC—AGE, SEX, AND RACE, U.S. 2006 (%)</i>	23
<i>TABLE 6 PERCENTAGE OF INDIVIDUALS WITH DEPRESSION BY AGE AND POVERTY STATUS, UNITED STATES 2006 (%)</i>	23
<i>TABLE 7 INDIVIDUALS 12 YEAR OF AGE AND OLDER REPORTING DIFFICULTY WITH THEIR WORK, HOME, AND SOCIAL ACTIVITIES BY SEX AND DEPRESSION SEVERITY, UNITED STATES, 2006 (%)</i>	24
<i>TABLE 8 INDIVIDUALS 12 YEARS OF AGE AND OLDER CONTACTING A MENTAL HEALTH PROFESSIONAL IN THE PAST 12 MONTHS, BY DEPRESSION SEVERITY, UNITED STATES 2006 (%)</i>	24
CHILDREN AND ADOLESCENTS	25
OLDER ADULTS	25
COSTS OF MENTAL ILLNESS.....	26
<i>TABLE 9 BEST ESTIMATE PREVALENCE RATES BASED ON EPIDEMIOLOGICAL CATCHMENT AREA, AGE 55+ (%)</i>	26
DEPRESSIVE DISORDERS	27
MAJOR DEPRESSION.....	27
Etiology and Neurobiology	28
<i>TABLE 10 RISK FACTORS FOR MAJOR DEPRESSIVE AND BIPOLAR DISORDERS</i>	28
<i>TABLE 11 PREFRONTAL CORTEX AND SEROTONIN INTERCONNECTIONS: IMPLICATIONS IN DEPRESSION</i>	29
<i>TABLE 11 (CONTINUED)</i>	30
Clinical Manifestations.....	31
BIPOLAR DISORDER	32
Etiology and Neurobiology	33
Clinical Manifestations	34
Bipolar I Disorder	34
Bipolar II Disorder.....	35
Bipolar II Disorder (Continued).....	36
SEASONAL AFFECTIVE DISORDER	37
Clinical Manifestations	37
ANXIETY DISORDERS.....	38
Panic Disorder	38
Etiology and Neurobiology	39
Etiology and Neurobiology (Continued)	40
Clinical Manifestations.....	41
Generalized Anxiety Disorder.....	41
Etiology and Neurobiology	41
Etiology and Neurobiology (Continued).....	42
Clinical Manifestations.....	43
Obsessive-Compulsive Disorder.....	43
Etiology and Neurobiology	44

Clinical Manifestations.....	45
Specific and Social Phobias	45
<i>TABLE 12 CLINICAL NAMES FOR COMMON PHOBIAS</i>	<i>46</i>
Post-Traumatic Stress Disorder	47
GENERIC INFLUENCE	47
ELDERLY IMPACT.....	48
DEPRESSION	48
ANXIETY.....	49
CHILDREN AND ADOLESCENT IMPACT	49
DEPRESSION	49
Symptoms of Depression in Children	50
Symptoms of Depression in Children (Continued)	51
ANXIETY.....	52
ALTERNATIVE AND COMPLEMENTARY THERAPIES	53
ST. JOHN'S WORT (HYPERFORIN AND HYPERICIN).....	53
VALERIAN ROOT.....	53
5-HTP.....	54
RHODIOLA ROSEA.....	54
SAM-E.....	54
BACOPA.....	54
GINSENG.....	55
B VITAMINS - B1, B3, B5, B6, B9, AND B12	55
ZINC.....	55
MAGNESIUM	56
KAVA KAVA.....	56
OVERUSE OF ANTIDEPRESSANTS—ANOTHER VIEW.....	56
LEGISLATIVE ISSUES	57
COMPLIANCE ISSUES	58
COMPLIANCE ISSUES (CONTINUED).....	59
PRESCRIBING TRENDS.....	60
DEPRESSION RISK DUE TO BRAIN THINNING.....	60
DEPRESSION RISK DUE TO ... (CONTINUED)	61
SUICIDAL BEHAVIOR AND ANTIDEPRESSANTS.....	62
NOVEL APPROACH IN TEEN SUICIDE.....	63
COMBINATION THERAPY.....	64
REMOTE SUPPORT FOR DEPRESSION	65
TREATMENTS AND PRODUCTS FOR DEPRESSIVE DISORDERS	66
TREATMENTS AND PRODUCTS FOR...(CONTINUED).....	67
PRESCRIPTION PRODUCTS.....	68
Selective Serotonin Reuptake Inhibitors.....	68
Side Effects.....	68
Pharmacologies	69
Serotonin-Norepinephrine Reuptake Inhibitors	69
Tricyclic Antidepressants.....	69

Chemical Aspects.....	69
Mechanism of Action.....	70
Actions and Side Effects	70
Pharmacologics	71
Monoamine Inhibitors	72
Chemical Aspects.....	73
Pharmacologics	73
Side Effects.....	74
Others.....	74
Marketed Antidepressants.....	75
Marketed Antidepressants (Continued)	76
Marketed Antidepressants (Continued)	77
Marketed Antidepressants (Continued)	78
<i>TABLE 13 SELECTED MARKETED ANTIDEPRESSANT DRUGS (\$</i>	
<i>MILLIONS)</i>	79
ALTERNATIVE TREATMENTS.....	80
Light Therapy	80
Electroconvulsive Therapy	80
Acupressure	81
Acupuncture.....	81
Biofeedback	81
Nutrition	81
Reflexology	82
Self-Help Groups	82
Animal-Assisted Therapies	83
Expressive Therapies	83
Art Therapy.....	83
Dance/Movement Therapy.....	83
Music/Sound Therapy	83
Guided Imagery or Visualization.....	84
Massage Therapy.....	84
Technology-Based Applications	84
Telemedicine	84
Telephone Counseling.....	84
Electronic Communications.....	85
Radio Psychiatry	85
Vagus Nerve Stimulation (VNS).....	85
Transcranial Magnetic Stimulation (TMS)	85
Deep Brain Stimulation	85
TREATMENTS AND PRODUCTS FOR ANXIETY DISORDERS.....	86
PRESCRIPTION PRODUCTS.....	86
Barbiturates.....	86
Benzodiazepines	86
Tricyclic Antidepressants.....	87

Selective Serotonin Reuptake Inhibitors	87
Serotonin-Norepinephrine Reuptake Inhibitors	88
Effexor	88
Cymbalta	89
Antihistamines	89
Anticonvulsants/Bipolar	89
Lamictal	89
Lithium.....	89
Beta-Blockers.....	90
Antipsychotics.....	90
Abilify	90
BuSpar.....	91
Geodon.....	91
Risperdal	91
Seroquel.....	91
Zyprexa.....	91
<i>TABLE 14 SELECTED MARKETED ANTI-ANXIETY DRUGS.....</i>	<i>92</i>
<i>TABLE 14 (CONTINUED).....</i>	<i>93</i>
CHAPTER FOUR: MARKET SIZE AND GROWTH	94
TOTAL MARKET.....	94
Total Antidepressant and Anti-anxiety Drug Market by Product Classification	94
<i>TABLE 15 TOTAL MARKET FOR DEPRESSIVE AND ANXIETY DISORDERS, THROUGH 2014 (\$ MILLIONS).....</i>	<i>94</i>
<i>FIGURE 4 TOTAL MARKET FOR DEPRESSIVE AND ANXIETY DISORDERS, 2007-2014 (\$ MILLIONS).....</i>	<i>95</i>
<i>TABLE 16 TOTAL MARKET SHARE BY CATEGORY, 2009 AND 2014 (%).....</i>	<i>95</i>
<i>FIGURE 5 TOTAL MARKET SHARE BY CATEGORY, 2009 AND 2014 (%).....</i>	<i>96</i>
TOTAL ANTIDEPRESSANT AND ANTI-ANXIETY DRUG MARKET BY GEOGRAPHIC SEGMENTS	96
<i>FIGURE 6 GLOBAL MARKET SIZE OF THERAPIES FOR DEPRESSIVE AND ANXIETY DISORDERS BY REGION, 2007-2014 (\$ MILLIONS).....</i>	<i>97</i>
<i>TABLE 18 TOTAL MARKET SHARE BY REGION, 2009 AND 2014 (%).....</i>	<i>98</i>
<i>FIGURE 7 TOTAL MARKET SHARE BY REGION, 2009 AND 2014 (%).....</i>	<i>98</i>
DEPRESSION MARKET.....	99
ANTIDEPRESSANT DRUG MARKET BY PRODUCT CLASSIFICATION	99
<i>TABLE 19 GLOBAL MARKET FOR ANTIDEPRESSANTS BY PRODUCT, THROUGH 2014 (\$ MILLIONS).....</i>	<i>100</i>
<i>FIGURE 8 GLOBAL MARKET FOR ANTIDEPRESSANTS BY PRODUCT, 2007-2014 (\$ MILLIONS).....</i>	<i>100</i>

<i>TABLE 20 GLOBAL MARKET SHARE OF ANTIDEPRESSANTS BY PRODUCT, THROUGH 2014 (%)</i>	101
<i>FIGURE 9 GLOBAL MARKET SHARE OF ANTIDEPRESSANTS BY PRODUCT, 2007-2014 (%)</i>	101
ANTIDEPRESSANT DRUG MARKET BY GEOGRAPHIC SEGMENTS	101
United States	102
European Union.....	102
Japan.....	102
Rest of World.....	103
<i>TABLE 21 GLOBAL MARKET FOR ANTIDEPRESSANTS BY REGION, 2007-2014 (\$ MILLIONS)</i>	103
<i>FIGURE 10 GLOBAL MARKET FOR ANTIDEPRESSANTS BY REGION, 2007-2014 (\$ MILLIONS)</i>	104
<i>TABLE 22 GLOBAL MARKET SHARE OF GLOBAL ANTIDEPRESSANTS BY REGION, 2007-2014 (%)</i>	104
<i>FIGURE 11 GLOBAL MARKET SHARE OF GLOBAL ANTIDEPRESSANTS BY REGION, 2007-2014 (%)</i>	105
ANTIANXIETY MARKET	105
ANTIANXIETY DRUG MARKET BY PRODUCT CLASSIFICATION	105
<i>TABLE 23 GLOBAL MARKET FOR ANTIANXIETY DRUGS BY PRODUCT TYPE, THROUGH 2014 (\$ MILLIONS)</i>	106
<i>TABLE 24 GLOBAL MARKET SHARE OF ANTIANXIETY DRUGS BY PRODUCT TYPE, 2007-2014 (%)</i>	107
<i>FIGURE 12 GLOBAL MARKET FOR ANTIANXIETY DRUGS BY PRODUCT TYPE, 2007-2014 (\$ MILLIONS)</i>	107
<i>FIGURE 13 GLOBAL MARKET SHARE OF ANTIANXIETY DRUGS BY PRODUCT TYPE, 2007-2014 (%)</i>	108
ANTIANXIETY DRUG MARKET BY GEOGRAPHIC SEGMENTS	108
United States	108
European Union.....	109
Japan.....	109
Rest of World.....	109
<i>TABLE 25 GLOBAL MARKET SIZE OF ANTIANXIETY DRUGS BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	110
<i>FIGURE 14 GLOBAL MARKET SIZE OF ANTIANXIETY DRUGS BY REGION, 2007-2014 (\$ MILLIONS)</i>	110
<i>TABLE 26 GLOBAL MARKET SHARE OF GLOBAL ANTIANXIETY DRUGS BY REGION, 2007-2014 (%)</i>	111
<i>FIGURE 15 GLOBAL MARKET SHARE OF GLOBAL ANTIANXIETY DRUGS BY REGION, 2007-2014 (%)</i>	111
CHAPTER FIVE: RESEARCH AND DEVELOPMENT	112

GEODON.....	112
GEPIRONE ER.....	112
RISPERDAL CONSTA.....	112
SAPHRIS.....	113
SEROQUEL XR.....	113
TRAZODONE ONCE DAILY.....	113
AGI0178.....	113
CORLUX.....	114
INVEGA.....	114
LU AA21004.....	114
LYRICA.....	114
NUVIGIL.....	115
SAREDUTANT.....	115
VILAZODONE.....	115
<i>TABLE 27 THERAPIES IN DEVELOPMENT FOR DEPRESSION AND ANXIETY, 2009.....</i>	<i>116</i>
<i>TABLE 27 (CONTINUED).....</i>	<i>117</i>
NOVEL PRODUCTS IN DEVELOPMENT.....	118
NOVEL PRODUCTS IN DEVELOPMENT (CONTINUED).....	119
CHAPTER SIX: COMPETITIVE ANALYSIS.....	120
TOTAL COMPETITIVE ANALYSIS.....	120
<i>TABLE 28 TOTAL COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION AND ANXIETY DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 (\$ MILLIONS/%).....</i>	<i>120</i>
<i>FIGURE 16 TOTAL COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION AND ANXIETY DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 (%).....</i>	<i>121</i>
DEPRESSION COMPETITIVE ANALYSIS.....	121
<i>TABLE 29 COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 (\$ MILLIONS/%).....</i>	<i>122</i>
<i>FIGURE 17 COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 (%).....</i>	<i>123</i>
<i>TABLE 30 COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION DISORDERS BY THE TOP FOUR DRUG MANUFACTURERS' MARKET SHARE, 2008 (\$ MILLIONS/%).....</i>	<i>123</i>
<i>FIGURE 18 COMPETITIVE ANALYSIS OF THERAPIES FOR DEPRESSION DISORDERS BY THE TOP FOUR DRUG MANUFACTURERS' MARKET SHARE, 2008 (%).....</i>	<i>124</i>
ANTIANXIETY COMPETITIVE ANALYSIS.....	124

<i>TABLE 31 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 (\$ MILLIONS/%)</i>	125
<i>TABLE 32 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY DISORDERS BY THE TOP FOUR DRUG MANUFACTURER MARKET SHARE, 2008 (\$ MILLIONS/%)</i>	126
<i>FIGURE 19 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 (%)</i>	126
<i>FIGURE 20 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY DISORDERS BY THE TOP FOUR DRUG MANUFACTURER MARKET SHARE, 2008 (%)</i>	127
CHAPTER SEVEN: PATENT ANALYSIS	128
<i>TABLE 33 SELECTED MANUFACTURER PATENTS FOR TREATMENT OF DEPRESSION AND ANXIETY</i>	128
CHAPTER EIGHT: COMPANY PROFILES	129
ASTRAZENECA.....	129
BRIEF HISTORY	129
PRODUCTS	129
COMPANY REVENUE HISTORY.....	129
<i>TABLE 34 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	130
RESEARCH AND DEVELOPMENT	130
BRISTOL-MYERS SQUIBB COMPANY	130
BRIEF HISTORY	130
PRODUCTS.....	131
COMPANY REVENUE HISTORY	131
<i>TABLE 35 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	131
RESEARCH AND DEVELOPMENT	132
DOV PHARMACEUTICAL, INC.	132
BRIEF HISTORY	132
PRODUCTS	132
RESEARCH AND DEVELOPMENT	132
ELI LILLY & COMPANY.....	132
BRIEF HISTORY	133
PRODUCTS.....	133
COMPANY REVENUE HISTORY	133
<i>TABLE 36 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	134
RESEARCH AND DEVELOPMENT	134
FABRE-KRAMER PHARMACEUTICALS, INC.	134
BRIEF HISTORY	134
PRODUCTS	134
RESEARCH AND DEVELOPMENT	135
FOREST PHARMACEUTICALS, INC.	135

BRIEF HISTORY	135
PRODUCTS	135
COMPANY REVENUE HISTORY	136
<i>TABLE 37 COMPANY REVENUES, 2007 AND 2008 (\$ BILLIONS)</i>	<i>136</i>
RESEARCH AND DEVELOPMENT	136
GLAXOSMITHKLINE.....	136
BRIEF HISTORY	136
PRODUCTS	137
COMPANY REVENUE HISTORY	137
<i>TABLE 38 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	<i>138</i>
RESEARCH AND DEVELOPMENT	138
JAZZ PHARMACEUTICALS, INC.	138
BRIEF HISTORY	138
PRODUCTS	139
COMPANY REVENUE HISTORY	139
<i>TABLE 39 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	<i>139</i>
RESEARCH AND DEVELOPMENT	139
JOHNSON & JOHNSON	139
BRIEF HISTORY	140
PRODUCTS	140
COMPANY REVENUE HISTORY.....	140
<i>TABLE 40 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	<i>140</i>
RESEARCH AND DEVELOPMENT	140
H. LUNDBECK A/S	141
BRIEF HISTORY	141
PRODUCTS	141
COMPANY REVENUE HISTORY	142
<i>TABLE 41 COMPANY REVENUES 2007 AND 2008 (\$ MILLIONS)</i>	<i>142</i>
RESEARCH AND DEVELOPMENT	142
MERCK & COMPANY, INC.....	142
BRIEF HISTORY	142
PRODUCTS	143
COMPANY REVENUE HISTORY	143
<i>TABLE 42 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	<i>143</i>
RESEARCH AND DEVELOPMENT	143
PFIZER, INC.	144
BRIEF HISTORY	144
PRODUCTS	144
COMPANY REVENUE HISTORY	144
<i>TABLE 43 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	<i>145</i>
RESEARCH AND DEVELOPMENT	145
ROCHE, INC.	145
BRIEF HISTORY	145
PRODUCTS	146

COMPANY REVENUE HISTORY.....	146
<i>TABLE 44 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	<i>146</i>
RESEARCH AND DEVELOPMENT	146
SANOFI-AVENTIS	147
BRIEF HISTORY	147
PRODUCTS	147
COMPANY REVENUE HISTORY	147
<i>TABLE 45 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	<i>148</i>
RESEARCH AND DEVELOPMENT	148
SEPRACOR, INC.	148
BRIEF HISTORY	148
PRODUCTS	149
COMPANY REVENUE HISTORY	149
<i>TABLE 46 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	<i>149</i>
RESEARCH AND DEVELOPMENT	149
SCHERING-PLOUGH CORP.....	150
BRIEF HISTORY	150
PRODUCTS	150
COMPANY REVENUE HISTORY	150
<i>TABLE 47 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	<i>151</i>
RESEARCH AND DEVELOPMENT	151
WYETH	151
BRIEF HISTORY	151
PRODUCTS	151
COMPANY REVENUE HISTORY	152
<i>TABLE 48 COMPANY REVENUES, 2007 AND 2008 (\$ MILLIONS)</i>	<i>152</i>
RESEARCH AND DEVELOPMENT	152
APPENDIX A.....	153
ALTERNATIVE APPROACHES TO MENTAL HEALTH	
ORGANIZATIONS	153
ALTERNATIVE APPROACHES TO ... (CONTINUED).....	154
APPENDIX B.....	155
COMPANY LISTINGS	155
<i>TABLE 49 COMPANY LISTINGS</i>	<i>155</i>
<i>TABLE 49 (CONTINUED)</i>	<i>156</i>
<i>TABLE 49 (CONTINUED)</i>	<i>157</i>
<i>TABLE 49 (CONTINUED)</i>	<i>158</i>
<i>TABLE 49 (CONTINUED)</i>	<i>159</i>
<i>TABLE 49 (CONTINUED)</i>	<i>160</i>
<i>TABLE 49 (CONTINUED)</i>	<i>161</i>